Table II.

Results of univariate analysis for event-free survival (EFS) and overall survival (OS) outcomes of the 21 patients with metastatic osteosarcoma at presentation.

Variables	Patient no. (%) (n=21)	Median EFS, months	Log-rank P-value	Median OS, months	Log-rank P-value
Age, years			0.089		0.48
<18	10 (48.0)	4.0		17.5
≥18	11 (52.0)	9.0		32.9
Gender			0.83		0.75
Male	12 (57.0)	5.0		19.6
Female	9 (43.0)	7.7		16.3
Histological subtype			0.84		0.040
Osteoblastic	6 (29.0)	5.4		10.5
Other	15 (71.0)	4.0		32.9
Alkaline phosphatase, IU/l			0.11		0.26
<500	18 (86.0)	7.2		32.9
≥500	3 (14.0)	5.0		17.0
Primary tumor site			0.53		0.57
Femur	10 (48.0)	7.2		19.6
Other	11 (52.0)	4.0		32.9
Status of primary tumor			0.31		0.32
Controlled	15 (71.0)	5.4		19.6
Uncontrolled	6 (29.0)	5.0		17.7
Necrosis following CTX			0.099		0.21
≥90%	3 (14.0)	35.0		42.0
Other	18 (86.0)	5.4		17.5
Achievement of CR			0.026		0.046
Yes	4 (19.0)	35		42.0
No	17 (81.0)	5.0		17.5
First-line chemotherapy			0.48		0.61
Cisplatin + doxorubicin	11 (52.0)	7.2		32.9
Cisplatin, doxorubicin + MTX	7 (33.0)	3.7		19.6
IE chemotherapy	1 (5.0)
No chemotherapy	2 (10.0)
Site of metastasis			0.35		0.014
Lung only	15 (71.0)	5.0		33.6
Extrapulmonary	6 (29.0)	5.4		10.5
Bone metastasis			0.22		0.07
Yes	5 (24.0)	5.4		17
No	16 (76.0)	7.2		33.6
Number of metastatic sites			0.44		0.06
One	16 (76.0)	5.4		33.6
More than one	5 (24.0)	6.4		17

CTX, chemotherapy; CR, complete remission; MTX, methotrexate; IE, ifosfamide and etoposide.